Мультимодальный антидепрессант вортиоксетин


Е.А. Ушкалова (1), А.В. Ушкалова (2)

(1) Кафедра общей и клинической фармакологии РУДН, Москва; (2) ФГБУ «Московский НИИ психиатрии» Минздрава России

Литература



  1. Correll CU. Vortioxetine: A New Antidepressant Choice in the United States. Medscape Oct 02, 2013. http://www.medscape.com/viewarticle/811959

  2. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice // Am. J. Psychiatry. — 2006. — Vol. 163. — P. 28—40.

  3. Nutt D.J. Beyond psychoanaleptics – can we improve antidepressant drug nomenclature? // J. Psychopharmacol. — 2009. — Vol. 23. — P. 343—45.

  4. Chang T., Fava M. Review The future of psychopharmacology of depression // J. Clin. Psychiatry. — 2010. — Vol. 71(8). — P. 971—75.

  5. Bang-Andersen B., Ruhland T., Jorgensen M., et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder // J. Med. Chem. — 2011. — Vol. 54. — P. 3206—21.

  6. Mork A., Montezinho L.P., Miller S., et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats // Pharmacol. Biochem. Behav. — 2013. — Vol. 105. — P. 41—50.

  7. Pehrson A.L., Cremers T., Betry C., et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters – a rat microdialysis and electrophysiology study // Eur. Neuropsychopharmacol. — 2013. — Vol. 23(2). — P. 133—45.

  8. Bang-Andersen B., Ruhland T., Jorgensen M., et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder // J. Med. Chem. —2011. — Vol. 54(9). — P. 3206—12.

  9. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder // Int. J. Neuropsychopharmacol. — 2013. — Vol. 30. — P. 1—10. [Epub ahead of print

  10. Areberg J., Luntang-Jensen M., Sogaard B., Nilausen DO. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects // Basic Clin. Pharmacol. Toxicol. — 2012. — Vol. 110(4). — P. 401—04.

  11. Betry C., Pehrson A.L., Etievant A., Ebert B., Sanchez C., Haddjeri N. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine invovles 5-HT3 receptor antagonism // Int. J. Neuropsychopharmacol. — 2013. — Vol. 16(5). — P. 1115–27.

  12. Pehrson A.L., Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction // CNS Spectr. — 2013. — Aug 1 [Epub ahead of print].

  13. Artigas F. Serotonin receptors involved in antidepressant effects // Pharmacol. Ther. — 2013. — Vol. 137(1). — P. 119—31.

  14. Mork A., Pehrson A., Brennum L.T., et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder // J. Pharmacol. Exp. Ther. — 2012. — Vol. 340(3). — P. 666—75.

  15. du Jardin K.G., Jensen J.B., Sanchez C, Pehrson A.L. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism // Eur. Neuropsychopharmacol. — 2013. — Aug 2. [Epub ahead of print].

  16. Areberg J., Sogaard B., Hojer A.M. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers // Basic Clin. Pharmacol. Toxicol. — 2012. — Vol. 111. — P. 198—205.

  17. Hvenegaard M.G., Bang-Andersen B., Pedersen H., et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004 // Drug Metab. Dispos. — 2012. — Vol. 40. — P. 1357—65.

  18. Chen G., Lee R., Hojer A.M., et al. Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant // Eur. Neuropsychopharmacol. — 2012. — Vol. 22. — P. 482—91.

  19. Henigsberg N., Mahableshwarkar A.R., Jacob-sen P., Chen Y., Thase M.E. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder // J. Clin. Psychiatry. — 2012. — Vol. 73. — P. 953—59.

  20. Alvarez E., Perez V., Dragheim M., Loft H., Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder // Int. J. Neuropsychopharmacol. — 2012. — Vol. 15. — P. 589—600.

  21. Mahableshwarkar A.R., Jacobsen P.L., Serenko M., Chen Y., Trivedi M. A randomized, double-blind, parallel group study comparing the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Program and abstracts of the 166th Annual American Psychiatric Association Meeting; May 18–22, 2013; San Francisco, California. — Poster NR9-02.

  22. Jacobsen P.L., Mahableshwarkar A.R., Serenko M., Chen Y., Trivedi M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Program and abstracts of the 166th Annual American Psychiatric Association Meeting; May 18–22, 2013; San Francisco, California. — Poster NR9-06 3.

  23. Baldwin D.S., Loft H., Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD) // Eur. Neuropsychopharmacol. — 2012. — Vol. 22(7). — P. 482—91.

  24. Mahableshwarkar A.R., Jacobsen P.L., Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder //Curr. Med. Res. Opin. — 2013. — Vol. 29. — P. 217—26.

  25. Jain R., Mahableshwarkar A.R., Jacobsen P.L., Chen Y., Thase M.E. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder // Int. J. Neuropsychopharmacol. — 2013. — Vol. 16. — P. 313—21.

  26. Katona C., Hansen T., Olsen C.K. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder // Int.Clin. Psychopharmacol. — 2012. — Vol. 27. — P. 215—23.

  27. Baldwin D.S., Loft H., Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD) // Eur. Neuropsychopharmacol. — 2012. — Vol. 22(7). — P. 482—91.

  28. Baldwin D.S., Hansen T., Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder // Curr. Med. Res. Opin. — 2012. — Vol. 28. — P. 1717—24.

  29. Boulenger J.P., Loft H., Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder // J. Psychopharmacol. — 2012. — Vol. 26(11). — P. 1408—16.

  30. Haggstrom L., Nielsen R.Z., Dragheim M. A randomised, double-blind, active controlled study of vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day) in adults with major depressive disorder with inadequate response to antidepressant treatment. Program and abstracts of the 21st European Congress of Psychiatry; April 6–9, 2013; Nice, France. Abstract 3009.

  31. Novartis drops future blockbuster agomelatine http://www.scripintelligence.com/home/Novartis-drops-future-blockbuster-agomelatine-322880 25 October 2011.

  32. Cipriani A., Koesters M., Furukawa T.A., et al. Duloxetine versus other anti-depressive agents for depression // Cochrane Database Syst. Rev. — 2012. Oct 17. CD006533.

  33. Bijlsma E.Y., Chan J.S., Olivier B., et al. Sexual side effects of serotonergic antidepressants: Mediated by inhibition of serotonin on central dopamine release? // Pharmacol. Biochem. Behav. — 2013. Oct 12. pii: S0091-3057(13)00238–34.

  34. Jorge R.E., Robinson R.G. Treatment of late-life depression: a role of non-invasive brain stimulation techniques // Int. Rev. Psychiatry. — 2011. — 23(5). — P. 437—43.

  35. Theunissen E.L., Street D., Hojer A.M., et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition // Clin. Pharmacol. Ther. — 2013. — Vol. 93(6). — P. 493—501.

  36. Guilloux J.P., Mendez-David I., Pehrson A., et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice //Neuropharmacology. — 2013. — Vol. 73. — P. 147—59.

  37. Baldwin DS, Nutt DJ. On assessing potential efficacy for vortioxetine in generalized anxiety di-sorder // Eur. Neuropsychopharmacol. — 2012. — Vol. 22(12). — P. 841—43.

  38. Rothschild A.J., Mahableshwarkar A.R., Jacobsen P., et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States // Eur. Neuropsychopharmacol. — 2012. — Vol. 22(12). — P. 858—66.

  39. Bidzan L., Mahableshwarkar A.R., Jacobsen P., et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial // Eur. Neuropsychopharmacol. — 2012. — Vol. 22(12). — P. 847—57.


Об авторах / Для корреспонденции


Е.А. Ушкалова – д.м.н., проф. кафедры общей и клинической фармакологии РУДН
А.В. Ушкалова – м.н.с. отдела терапии психических заболеваний ФГБУ «Московский НИИ психиатрии» Минздрава России


Бионика Медиа